For example, one recent study shows that the inhibition of MEK1/2 pathway or the activation of PI3K pathway leads to SHP repression in metabolic conditions such as advanced nonalcoholic fatty liver disease (NAFLD) [38]. Here, NR0B2 is linked to metabolic dysfunction-associated steatotic liver disease.